|
|
|
Insomnia compound (Org 50081) shows promise as it moves into Phase III clinical trials
|
Wednesday, December 20, 2006 (Oss, the Netherlands)
 Organon, the human healthcare business unit of Akzo Nobel, has moved Org 50081, a Serotonin 2 blocker (S2B) for the treatment of insomnia, into Phase III clinical development. About 70 million Americans each year suffer from symptoms of insomnia, which can lead to problems with daytime functioning. Insomnia tends to occur more often in elderly and women and is associated with an increased risk for developing other illnesses such as depression. The number of people treated for insomnia is expected to substantially increase over the next several years. |
| |
| Phase III clinical studies for the novel oral contraceptive of Organon, NOMAC/E2, now in full swing - NOMAC/E2 Phase II clinical trial program indicated good ovulation inhibition combined with an acceptable monthly bleeding pattern and safety profile |
| Tuesday, December 05, 2006 (Oss, The Netherlands) |
| |
| Organon continues with the development of asenapine |
| Tuesday, November 28, 2006 (Arnhem, The Netherlands) |
| |
| Organon and Pfizer discontinue their collaboration on asenapine |
| Tuesday, November 28, 2006 (New York, New York, USA and Arnhem, The Netherlands) |
| |
| NuvaRing® users are ‘one in a million’ - Over one million women using NuvaRing® – the once-a-month contraceptive |
| Wednesday, February 08, 2006 (Oss, The Netherlands) |
| |
|
|
